Xlife Sciences AG / Key word(s): Miscellaneous21-Nov-2022 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.The Board of Directors of Xlife Sciences AG (SIX: XLS), a leading European life sciences incubator and accelerator ba.
Xlife Sciences AG / Key word(s): Half Year Results28-Sep-2022 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Xlife Sciences (SIX: XLS) today published its results for the first half of 2022 ending 30 June 2022. Oliver R. B.
DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Half Year ReportNewron provides H1 2022 results and updates on R&D and business activities 15.09.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Milan, Italy, September 15, 2022, 7 am CET – Newron Pharmaceuticals.
DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): PersonnelNewron extends Senior Management team and strengthens commitment to ESG 01.07.2022 / 07:00 The issuer is solely responsible for the content of this announcement.Newron extends Senior Management team andstrengthens commitment to ESGMilan, Italy, July 1.